K-numberK242463
Device nameARIA Radiation Therapy Management System (18.1)
ApplicantVarian Medical Systems, Inc.
Product codeMUJ
Device classClass II
Decision dateDec 13, 2024
DecisionSubstantially Equivalent
Regulation892.5050
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The ARIA Radiation Therapy Management System (18.1) is a software application that enables authorized users to enter, access, modify, store, and archive treatment plan and image data from diagnostic studies, treatment planning, simulation, plan verification, and treatment. It also stores treatment histories including dose delivered to defined sites and provides tools to verify performed treatments. The system does not directly act on patients but is used by trained medical professionals to manage radiotherapy treatment information.

Technological characteristics

The subject device (v18.1) incorporates four software enhancements compared to the predicate device (v18.0): Dynamic Collimator Support, Multi-Institution capability, Integrated Patient Setup Documentation (CTH Integration), and Enhanced Calibration Curve Support. Varian characterizes these as enhancements rather than fundamental changes to the device's principle of operation.

Test standards cited

ISO 14971:2019 (risk management), ISO 15223-1:2021 (symbols), ISO 20417:2021 (manufacturer information), IEC 62304:2006+A1:2016 (software lifecycle), IEC 62366-1:2015+A1:2020 (usability engineering), IEC 82304-1:2016 (health software safety), AAMI RT2:2017 (radiation therapy readiness), IEC 61217:2011 (radiotherapy equipment), IEC 62083:2009 (radiotherapy treatment planning systems), UL ANSI 2900-1:2017 and 2900-2-1:2017 (software cybersecurity), and IEC 81001-5-1:2021 (health software security).

Substantial equivalence argument

Varian argues substantial equivalence based on three points: (1) the principle of operation remains identical to the predicate device; (2) software verification and validation testing demonstrates the subject device is as safe and effective as the predicate; and (3) the identified differences are enhancements rather than fundamental alterations to functionality. No clinical or animal studies were required, relying instead on non-clinical software V&V testing to support equivalence.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →